FDA Approves Revuforj, a First-in-Class Menin Inhibitor, for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

FDA approval, Revuforj, Menin inhibitor, Acute leukemia, KMT2A translocation, Relapsed or refractory, Syndax Pharmaceuticals

FDA Approves PTC Therapeutics’ Kebilidi, the First Gene Therapy Delivered Directly to the Brain for AADC Deficiency

PTC Therapeutics, Kebilidi, Gene Therapy, AADC Deficiency, FDA Approval, Brain-Delivered Therapy, Rare Genetic Disorder

Abbott’s Esprit BTK Stent Demonstrates Sustained Benefits in Treating Severe Peripheral Artery Disease Below the Knee

Esprit BTK, dissolving stent, peripheral artery disease, below the knee, chronic limb-threatening ischemia, Abbott, LIFE-BTK trial, vascular health